Brought to you by 
Rare disease start-up Harmony raises $270mm in early equity funding
Oct 2017
Executive Summary
Concurrent with procuring an exclusive US license to Bioprojet's narcolepsy candidate pitolisant, Harmony Biosciences LLC (developing rare disease therapeutics) announced it raised $270mm in equity financing (assumed to be its Series A round) from 29 investors, including Valor Equity Partners, Fidelity Management & Research, HBM Healthcare Investments, Vivo Capital, venBio Partners, Novo Holdings, and Nan Fung Life Sciences.
Deal Industry
-
Biotechnology
- Drug Discovery Tools
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Rare disease start-up Harmony raises $270mm in early equity funding
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice